Eli Lilly (LLY)
924.37
-13.07 (-1.39%)
NYSE · Last Trade: Nov 9th, 6:24 PM EST
For long-term investors, there are plenty of reasons to buy and hold Eli Lilly for not only years but decades.
Via The Motley Fool · November 9, 2025
As of November 2025, Artificial Intelligence (AI) has rapidly transitioned from a futuristic concept to an indispensable tool in American healthcare, profoundly reshaping diagnostics, treatment, and administrative workflows. This transformative leap, however, particularly the increasing reliance on "surrendering care to algorithms," presents a complex ethical landscape and significant societal consequences that demand careful scrutiny and [...]
Via TokenRing AI · November 9, 2025
The weight loss drug company was counted out far too early in the summer, but investors are warming to it again.
Via The Motley Fool · November 9, 2025
Trump Announces Deals With Eli Lilly, Novo Nordisk To Lower Obesity Drug Pricesstocktwits.com
Via Stocktwits · November 6, 2025
The companies announced a huge deal that will have implications for investors.
Via The Motley Fool · November 9, 2025
Pharmaceutical company Organon (NYSE:OGN)
will be announcing earnings results this Monday before market hours. Here’s what you need to know.
Via StockStory · November 8, 2025
Eli Lilly stock and a pair of AI plays lead this watch list of stocks near buy points as the S&P 500 makes a stand at a key support level.
Via Investor's Business Daily · November 8, 2025
The stock didn't stay down for too long.
Via The Motley Fool · November 8, 2025
It could become the first trillion-dollar pharmaceutical company in the process.
Via The Motley Fool · November 8, 2025
Weight loss drugs generated about $10 billion for Lilly in the most recent quarter.
Via The Motley Fool · November 8, 2025
Nvidia CEO Jensen Huang cautioned Elon Musk against underestimating the challenges of semiconductor manufacturing, saying building a chip fab like TSMC's is "extremely hard."
Via Benzinga · November 8, 2025
The global drugmaker is facing some headwinds related to tough competition.
Via The Motley Fool · November 7, 2025
The S&P 500 has been on an impressive ascent, with market sentiment in November 2025 largely skewed towards cautious optimism. After a robust year of gains, driven significantly by the "mania around AI" and strong corporate earnings, many market participants anticipate the rally will continue. Despite a brief dip
Via MarketMinute · November 7, 2025
Shares of leading designer of graphics chips Nvidia (NASDAQ:NVDA)
fell 4.1% in the afternoon session after the stock retreated amid renewed concerns about stretched valuations in the AI space and geopolitical concerns as the U.S. government reportedly moved to block the company from selling even its less powerful, scaled-down artificial intelligence chips to China. The decision was aimed at stopping the sale of a reconfigured version of the advanced Blackwell chip, which had been designed specifically to avoid previous U.S. export controls. Reinforcing the news, Nvidia's CEO Jensen Huang stated there were "no active discussions" about selling these chips to Chinese customers. The development hit investor sentiment at a time when there were already wider concerns about high valuations for AI-related stocks. The news also coincided with a broader sell-off in the technology sector, which added to the downward pressure on the stock.
Via StockStory · November 7, 2025
As the calendar turns towards late 2025, leading financial experts are providing a detailed compass for investors, navigating a stock market characterized by cautious optimism, elevated valuations, and a dynamic interplay of technological innovation and macroeconomic shifts. The consensus points to a market that, while still offering growth avenues, demands
Via MarketMinute · November 7, 2025
Eli Lilly's eloralintide cut body weight by up to 20% in a Phase 2 trial, showing strong efficacy and potential to advance obesity treatment.
Via Benzinga · November 7, 2025
FDA adds six drugs to its priority voucher program as CMS and the White House unveil measures to speed reviews and lower prescription costs.
Via Benzinga · November 7, 2025
The drug has surpassed GlaxoSmithKline’s antibiotic Augmentin, according to a Reuters report on Friday, citing data from research firm Pharmarack.
Via Stocktwits · November 7, 2025
The feast that saw obesity-tied stocks skyrocket in 2024 is over. Investors' appetite for weight-loss drugs has waned.
Via Investor's Business Daily · November 7, 2025
Bank of America Securities called Lilly’s GLP-1 pricing deal “probably a good tradeoff overall,” keeping a ‘Buy’ rating and $950 target.
Via Stocktwits · November 6, 2025
Citi calls Trump’s GLP-1 pricing deal “less bad than feared,” while Needham warns it could erode Hims’ cost advantage.
Via Stocktwits · November 6, 2025
Trump secures a major deal with Eli Lilly and Novo Nordisk to cut obesity drug costs as Medicare expands coverage for Zepbound and Wegovy by 2026.
Via Benzinga · November 6, 2025
Is the fourth time the charm for this Danish pharmaceutical giant?
Via The Motley Fool · November 6, 2025
The Trump administration struck deals with Eli Lilly and Novo Nordisk to lower obesity drug prices and expand Medicare coverage starting in 2026.
Via Benzinga · November 6, 2025
The Trump administration announced deals Thursday with Eli Lilly and Novo Nordisk to slash the prices of their obesity drugs.
Via Investor's Business Daily · November 6, 2025